DNTHDianthus Therapeutics, Inc....

Nasdaq magentatx.com


$ 24.36 $ -0.64 (-2.57 %)    

Friday, 10-May-2024 15:59:48 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 24.29
$ 26.22
$ 0.00 x 0
$ 0.00 x 0
$ 23.96 - $ 26.22
$ 0.61 - $ 33.77
98,030
na
623.41M
$ 1.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-08-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-03-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-03-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-19-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wedbush-maintains-outperform-on-dianthus-therapeutics-raises-price-target-to-38

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from...

 dianthus-therapeutics-q1-eps-054-misses-044-estimate-sales-87400k-beat-46000k-estimate

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate ...

 raymond-james-maintains-outperform-on-dianthus-therapeutics-raises-price-target-to-51

Raymond James analyst Steven Seedhouse maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price ...

 why-cutera-shares-are-trading-lower-by-over-26-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected four...

 worthington-steel-posts-upbeat-results-joins-summit-midstream-partners-fedex-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

 wedbush-maintains-outperform-on-dianthus-therapeutics-raises-price-target-to-33

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from...

 dianthus-therapeutics-q4-eps-071-beats-101-estimate-sales-45700k-beat-31000k-estimate

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of...

 stifel-initiates-coverage-on-dianthus-therapeutics-with-buy-rating-announces-price-target-of-44

Stifel analyst Alex Thompson initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price...

 wedbush-maintains-outperform-on-dianthus-therapeutics-raises-price-target-to-24

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from...

 why-dianthus-therapeutics-dnth-stock-is-exploding-higher

Dianthus Therapeutics shares traded higher by 37% Monday. The company announced a $230 million private placement.

 dianthus-therapeutics-enters-agreement-for-private-investment-in-public-equity-financing-that-is-expected-to-result-in-gross-proceeds-of-230m

Pursuant to the terms of the securities purchase agreement, Dianthus is selling an aggregate of 14,500,500 shares of its common...

 jefferies-initiates-coverage-on-dianthus-therapeutics-with-buy-rating-announces-price-target-of-22

Jefferies analyst Maury Raycroft initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces P...

 antibody-player-dianthus-therapeutics-has-potential-amid-active-ma-landscape-in-complement-focused-firms-analyst

Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned mo...

 wedbush-initiates-coverage-on-dianthus-therapeutics-with-outperform-rating-announces-price-target-of-23

Wedbush analyst Laura Chico initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform rating and announces...

 dianthus-therapeutics-q3-eps-378-sales-92400k-beat-50000k-estimate

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(3.78) per share. The company reported quarterly sales of $9...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION